In vitro chemoresponse analysis of cervical cancer patient specimens

Perry W. Grigsby, Christine M. Gan, Todd D. Tillmanns, Giuseppe Del Priore

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: The objective of this study was to report the results of in vitro chemoresponse analysis of primary, metastatic, and recurrent human cervical cancers. Methods: There were 557 tumor specimens submitted for testing from August 2006 to June 2010. Single agents tested were cisplatin, carboplatin, paclitaxel, docetaxel, epirubicin, fluorouracil, 4-hydroxy ifosfamide (active metabolite of ifosfamide), SN-38 (active metabolite of irinotecan), topotecan, and vinorelbine. Doublets tested were carboplatin/paclitaxel and cisplatin/topotecan. Tumor response was determined from dose-response curves. Results were scored as responsive, intermediate, or nonresponsive. Chemoresponse was reported as the combined responsive and intermediate results. Results: Three hundred fifty-three (63.4%) of 557 submitted specimens were successfully assayed. Confirmation of histology and tumor status (primary, metastatic, or recurrent) was available for 273 specimens. The chemoresponse of the most active agents in primary cancers (n = 151) was 75% for SN-38, 71% for 4-hydroxy ifosfamide, 62% for topotecan, and 73% for carboplatin/paclitaxel. The chemoresponse of metastatic cancers (n = 66) was 54% for SN-38, 51% for 4-hydroxy ifosfamide, 44% for epirubicin, and 53% for carboplatin/paclitaxel. The chemoresponse for recurrent cancers (n = 56) was 44% for epirubicin, 41% for 4-hydroxy ifosfamide, 39% for vinorelbine, 39% for paclitaxel, 36% for topotecan, 46% for carboplatin/paclitaxel, and 35% for cisplatin/topotecan. The overall chemoresponse was greater in primary cancers (58%) than in recurrent cancers (35%) (P <0.0001). Conclusions: In vitro chemoresponse analysis of cervical cancer biospecimens is feasible. Chemoresponse results are variable depending on tumor status. Clinical studies of assaydirected therapy should be developed.

Original languageEnglish (US)
Pages (from-to)1665-1674
Number of pages10
JournalInternational Journal of Gynecological Cancer
Volume24
Issue number9
DOIs
StatePublished - Nov 1 2014

Fingerprint

irinotecan
Uterine Cervical Neoplasms
Topotecan
Carboplatin
Neoplasms
Epirubicin
Paclitaxel
docetaxel
In Vitro Techniques
Ifosfamide
Fluorouracil
Histology
4-hydroxyifosfamide

Keywords

  • Cervical cancer
  • Chemofx
  • Chemosensitivity
  • Chemotherapy
  • Individualized therapeutic response

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology
  • Medicine(all)

Cite this

In vitro chemoresponse analysis of cervical cancer patient specimens. / Grigsby, Perry W.; Gan, Christine M.; Tillmanns, Todd D.; Del Priore, Giuseppe.

In: International Journal of Gynecological Cancer, Vol. 24, No. 9, 01.11.2014, p. 1665-1674.

Research output: Contribution to journalArticle

Grigsby, Perry W. ; Gan, Christine M. ; Tillmanns, Todd D. ; Del Priore, Giuseppe. / In vitro chemoresponse analysis of cervical cancer patient specimens. In: International Journal of Gynecological Cancer. 2014 ; Vol. 24, No. 9. pp. 1665-1674.
@article{ab560886b29d4a719b08893dbdb876ad,
title = "In vitro chemoresponse analysis of cervical cancer patient specimens",
abstract = "Purpose: The objective of this study was to report the results of in vitro chemoresponse analysis of primary, metastatic, and recurrent human cervical cancers. Methods: There were 557 tumor specimens submitted for testing from August 2006 to June 2010. Single agents tested were cisplatin, carboplatin, paclitaxel, docetaxel, epirubicin, fluorouracil, 4-hydroxy ifosfamide (active metabolite of ifosfamide), SN-38 (active metabolite of irinotecan), topotecan, and vinorelbine. Doublets tested were carboplatin/paclitaxel and cisplatin/topotecan. Tumor response was determined from dose-response curves. Results were scored as responsive, intermediate, or nonresponsive. Chemoresponse was reported as the combined responsive and intermediate results. Results: Three hundred fifty-three (63.4{\%}) of 557 submitted specimens were successfully assayed. Confirmation of histology and tumor status (primary, metastatic, or recurrent) was available for 273 specimens. The chemoresponse of the most active agents in primary cancers (n = 151) was 75{\%} for SN-38, 71{\%} for 4-hydroxy ifosfamide, 62{\%} for topotecan, and 73{\%} for carboplatin/paclitaxel. The chemoresponse of metastatic cancers (n = 66) was 54{\%} for SN-38, 51{\%} for 4-hydroxy ifosfamide, 44{\%} for epirubicin, and 53{\%} for carboplatin/paclitaxel. The chemoresponse for recurrent cancers (n = 56) was 44{\%} for epirubicin, 41{\%} for 4-hydroxy ifosfamide, 39{\%} for vinorelbine, 39{\%} for paclitaxel, 36{\%} for topotecan, 46{\%} for carboplatin/paclitaxel, and 35{\%} for cisplatin/topotecan. The overall chemoresponse was greater in primary cancers (58{\%}) than in recurrent cancers (35{\%}) (P <0.0001). Conclusions: In vitro chemoresponse analysis of cervical cancer biospecimens is feasible. Chemoresponse results are variable depending on tumor status. Clinical studies of assaydirected therapy should be developed.",
keywords = "Cervical cancer, Chemofx, Chemosensitivity, Chemotherapy, Individualized therapeutic response",
author = "Grigsby, {Perry W.} and Gan, {Christine M.} and Tillmanns, {Todd D.} and {Del Priore}, Giuseppe",
year = "2014",
month = "11",
day = "1",
doi = "10.1097/IGC.0000000000000186",
language = "English (US)",
volume = "24",
pages = "1665--1674",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - In vitro chemoresponse analysis of cervical cancer patient specimens

AU - Grigsby, Perry W.

AU - Gan, Christine M.

AU - Tillmanns, Todd D.

AU - Del Priore, Giuseppe

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Purpose: The objective of this study was to report the results of in vitro chemoresponse analysis of primary, metastatic, and recurrent human cervical cancers. Methods: There were 557 tumor specimens submitted for testing from August 2006 to June 2010. Single agents tested were cisplatin, carboplatin, paclitaxel, docetaxel, epirubicin, fluorouracil, 4-hydroxy ifosfamide (active metabolite of ifosfamide), SN-38 (active metabolite of irinotecan), topotecan, and vinorelbine. Doublets tested were carboplatin/paclitaxel and cisplatin/topotecan. Tumor response was determined from dose-response curves. Results were scored as responsive, intermediate, or nonresponsive. Chemoresponse was reported as the combined responsive and intermediate results. Results: Three hundred fifty-three (63.4%) of 557 submitted specimens were successfully assayed. Confirmation of histology and tumor status (primary, metastatic, or recurrent) was available for 273 specimens. The chemoresponse of the most active agents in primary cancers (n = 151) was 75% for SN-38, 71% for 4-hydroxy ifosfamide, 62% for topotecan, and 73% for carboplatin/paclitaxel. The chemoresponse of metastatic cancers (n = 66) was 54% for SN-38, 51% for 4-hydroxy ifosfamide, 44% for epirubicin, and 53% for carboplatin/paclitaxel. The chemoresponse for recurrent cancers (n = 56) was 44% for epirubicin, 41% for 4-hydroxy ifosfamide, 39% for vinorelbine, 39% for paclitaxel, 36% for topotecan, 46% for carboplatin/paclitaxel, and 35% for cisplatin/topotecan. The overall chemoresponse was greater in primary cancers (58%) than in recurrent cancers (35%) (P <0.0001). Conclusions: In vitro chemoresponse analysis of cervical cancer biospecimens is feasible. Chemoresponse results are variable depending on tumor status. Clinical studies of assaydirected therapy should be developed.

AB - Purpose: The objective of this study was to report the results of in vitro chemoresponse analysis of primary, metastatic, and recurrent human cervical cancers. Methods: There were 557 tumor specimens submitted for testing from August 2006 to June 2010. Single agents tested were cisplatin, carboplatin, paclitaxel, docetaxel, epirubicin, fluorouracil, 4-hydroxy ifosfamide (active metabolite of ifosfamide), SN-38 (active metabolite of irinotecan), topotecan, and vinorelbine. Doublets tested were carboplatin/paclitaxel and cisplatin/topotecan. Tumor response was determined from dose-response curves. Results were scored as responsive, intermediate, or nonresponsive. Chemoresponse was reported as the combined responsive and intermediate results. Results: Three hundred fifty-three (63.4%) of 557 submitted specimens were successfully assayed. Confirmation of histology and tumor status (primary, metastatic, or recurrent) was available for 273 specimens. The chemoresponse of the most active agents in primary cancers (n = 151) was 75% for SN-38, 71% for 4-hydroxy ifosfamide, 62% for topotecan, and 73% for carboplatin/paclitaxel. The chemoresponse of metastatic cancers (n = 66) was 54% for SN-38, 51% for 4-hydroxy ifosfamide, 44% for epirubicin, and 53% for carboplatin/paclitaxel. The chemoresponse for recurrent cancers (n = 56) was 44% for epirubicin, 41% for 4-hydroxy ifosfamide, 39% for vinorelbine, 39% for paclitaxel, 36% for topotecan, 46% for carboplatin/paclitaxel, and 35% for cisplatin/topotecan. The overall chemoresponse was greater in primary cancers (58%) than in recurrent cancers (35%) (P <0.0001). Conclusions: In vitro chemoresponse analysis of cervical cancer biospecimens is feasible. Chemoresponse results are variable depending on tumor status. Clinical studies of assaydirected therapy should be developed.

KW - Cervical cancer

KW - Chemofx

KW - Chemosensitivity

KW - Chemotherapy

KW - Individualized therapeutic response

UR - http://www.scopus.com/inward/record.url?scp=84925968678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925968678&partnerID=8YFLogxK

U2 - 10.1097/IGC.0000000000000186

DO - 10.1097/IGC.0000000000000186

M3 - Article

VL - 24

SP - 1665

EP - 1674

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 9

ER -